Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2007

View Archived Issues

Experiments reveal characteristics of GA2-50, a possible treatment for cocaine abuse

Less toxicity seen with ISA-247 than with ciclosporin in vitro

Natural products in dermatology

UC Davis and M.I.N.D. Institute awarded grant for Fragile X research / News in Context

Palatin reacquires full rights to bremelanotide program

BrainStorm Cell Therapeutics takes initial steps toward FDA IND submission

Ownership of GI motility dysfunction program and TD-1792 retained by Theravance

Data from Accentia's phase III trial suggest fungal-induced inflammation as cause of CS

FDA grants Bioniche SPA for phase III study of MCC for bladder cancer

Update on Welichem's phase I trials of WBI-1001 for psoriasis

FDA extends review period of sNDA of Frova for short-term prevention of menstrual migraine

Ariad and FDA agree on SPA for phase III trial of deforolimus for metastatic sarcomas

Positive results for Moberg Derma's phase II trial of K-301 for seborrheic dermatitis

Basilea submits MAA for oral alitretinoin for chronic hand eczema in Europe

Novel therapeutic options for obesity and metabolic diseases described in recent patents

Wyeth and Progenics begin clinical trials of subcutaneous and intravenous methylnaltrexone

Novel agents for cardiovascular disorders disclosed in recent Takeda and Pfizer patents

Novel treatments for musculoskeletal and connective tissue disorders claimed in recent patents

Indolent NHL subject of Cell Therapeutics' phase III trial with pixantrone

EDSMB encourages continuation of phase III trial with Arena's lorcaserin

Promising phase II results with TPI-1020 support potential COPD trial

Wake-promoting profile of a novel histamine H3 antagonist

Auxilium begins dosing patients in two phase III trials of Xiaflex

Merck & Co. completes acquisition of NovaCardia

Astellas Pharma evaluates ASP-0485 for new indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...